Australia · Delayed Price · Currency is AUD Artrya Earnings Call Transcripts
Fiscal Year 2026
-
Converted all U.S. foundation partners to commercial contracts, launched first Plaque module revenues, and secured six major SAPPHIRE study sites. Strong cash position of AUD 76.5 million supports FDA submission and U.S. expansion, with full customer ramp-up targeted for FY 2027.
-
Technical integration and commercial negotiations with U.S. partners are progressing, with FDA clearance for the Salix Coronary Plaque module and a strong $80 million capital raise supporting U.S. expansion. Cash outflows rose due to scaling, but the company remains well-funded and targets break-even by FY2027.
Fiscal Year 2025
-
A real-time, AI-driven coronary CT platform is set to transform cardiac care by streamlining hospital workflows, improving patient outcomes, and delivering strong financial returns. With foundation customers committed and a robust U.S. go-to-market plan, break-even is targeted by FY2027.
-
The AGM highlighted a successful transition to commercial operations, strong U.S. market entry, and robust financial planning. Key FDA clearances, strategic partnerships, and a focus on high-margin SaaS growth were discussed, with profitability targeted for FY 2027-2028.
-
FDA clearance of the Salix Coronary Plaque Module enables real-time, automated plaque analysis at the point of care, opening a $4.4 billion U.S. market opportunity. The company is focused on structured rollout, reimbursement optimization, and expanding clinical studies, with first revenues expected in Q4 and further product submissions planned.
-
Transitioning to commercial operations, the company secured its first U.S. deal and is expanding partnerships in both the U.S. and Australia. FDA clearance for the plaque module and the SAPPHIRE study launch are key near-term priorities, with strong market interest and a solid cash position.
-
FDA clearance for the SCA product enables U.S. market entry and platform expansion, supported by a strong capital position and key customer agreements. SAPPHIRE study and U.S. commercialization efforts target significant scan volumes, with break-even expected in FY 2026 and cash flow positive in FY 2027.
-
FDA clearance for Salix Coronary Anatomy enables U.S. commercialization and sets the stage for rapid expansion, with additional products and studies underway. The company targets cash flow positive by FY26, focusing on strategic partnerships and customer support, while leveraging its regulatory platform for future growth.
-
Quarterly cash burn was reduced while maintaining FDA submission momentum, with SCA clearance expected by March and SCP by July. U.S. market expansion is prioritized, supported by a successful AUD 5M raise and strategic partnerships, while Australian operations focus on validation.
Fiscal Year 2024
-
The meeting highlighted progress toward FDA approval, a successful capital raise, and strategic U.S. partnerships. Shareholders approved all resolutions, and management emphasized a strong focus on U.S. market entry and product differentiation, with robust plans for 2025.